• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    5/29/24 12:31:13 PM ET
    $APLM
    $BHVN
    $CHRO
    $GENE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLM alert in real time by email

    Gainers

    • Innovative Eyewear (NASDAQ:LUCY) stock increased by 173.2% to $1.12 during Wednesday's regular session. The market value of their outstanding shares is at $19.6 million.
    • Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 53.94% to $0.32. The company's market cap stands at $7.5 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 34.56% to $0.27. The company's market cap stands at $4.2 million.
    • Apollomics (NASDAQ:APLM) shares increased by 28.89% to $0.34. The market value of their outstanding shares is at $36.7 million.
    • Onconetix (NASDAQ:ONCO) shares moved upwards by 25.07% to $0.2. The market value of their outstanding shares is at $4.5 million.
    • Chromocell Therapeutics (AMEX:CHRO) shares moved upwards by 24.99% to $1.7. The company's market cap stands at $9.8 million.

    Losers

    • TransCode Therapeutics (NASDAQ:RNAZ) shares declined by 32.0% to $1.32 during Wednesday's regular session. The market value of their outstanding shares is at $8.7 million.
    • Cue Health (NASDAQ:HLTH) stock decreased by 28.92% to $0.06. The market value of their outstanding shares is at $10.2 million.
    • Sharps Technology (NASDAQ:STSS) stock declined by 22.36% to $0.4. The market value of their outstanding shares is at $6.2 million.
    • Maravai LifeSciences (NASDAQ:MRVI) stock fell 16.56% to $8.99. The company's market cap stands at $1.1 billion.
    • Genetic Technologies (NASDAQ:GENE) stock decreased by 16.28% to $1.8. The market value of their outstanding shares is at $5.7 million.
    • Biohaven (NYSE:BHVN) shares declined by 15.0% to $32.25. The market value of their outstanding shares is at $2.8 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APLM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLM
    $BHVN
    $CHRO
    $GENE

    CompanyDatePrice TargetRatingAnalyst
    Biohaven Ltd.
    $BHVN
    2/6/2026$23.00Buy
    Goldman
    Biohaven Ltd.
    $BHVN
    1/21/2026$22.00Sector Perform → Outperform
    RBC Capital Mkts
    Biohaven Ltd.
    $BHVN
    12/3/2025$11.00Buy → Neutral
    H.C. Wainwright
    Biohaven Ltd.
    $BHVN
    11/26/2025$11.00Buy → Neutral
    UBS
    Biohaven Ltd.
    $BHVN
    11/6/2025$9.00Outperform → Mkt Perform
    Bernstein
    Biohaven Ltd.
    $BHVN
    11/5/2025$10.00Buy → Neutral
    BofA Securities
    Biohaven Ltd.
    $BHVN
    9/17/2025$28.00Buy
    Citigroup
    Biohaven Ltd.
    $BHVN
    9/3/2025$75.00Strong Buy
    Raymond James
    More analyst ratings

    $APLM
    $BHVN
    $CHRO
    $GENE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

    Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026.Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity.In previous clinical studies, taldefgrobep produced meaningful reductions in fat mass while increasing lean muscle mass in healthy adults and other non-obese populations; it has also demonstrated a highly favorable safety and tolerability profile in more than 700 trial participants.In nonclinical studi

    3/19/26 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

    TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by

    3/3/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $BHVN
    $CHRO
    $GENE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)

    4/A - Biohaven Ltd. (0001935979) (Issuer)

    3/9/26 6:12:05 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $APLM
    $BHVN
    $CHRO
    $GENE
    SEC Filings

    View All

    SEC Form PRE 14A filed by Onconetix Inc.

    PRE 14A - Onconetix, Inc. (0001782107) (Filer)

    3/18/26 7:55:08 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Biohaven Ltd.

    DEFA14A - Biohaven Ltd. (0001935979) (Filer)

    3/13/26 4:57:48 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Biohaven Ltd.

    DEF 14A - Biohaven Ltd. (0001935979) (Filer)

    3/13/26 4:54:52 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $BHVN
    $CHRO
    $GENE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Biohaven with a new price target

    Goldman initiated coverage of Biohaven with a rating of Buy and set a new price target of $23.00

    2/6/26 8:10:57 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Biohaven from Sector Perform to Outperform and set a new price target of $22.00

    1/21/26 8:29:40 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Biohaven from Buy to Neutral and set a new price target of $11.00

    12/3/25 7:48:22 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $BHVN
    $CHRO
    $GENE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $APLM
    $BHVN
    $CHRO
    $GENE
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

    Organizational restructuring and operating cost reduction ahead of plan Focus on operational excellence, revenue growth, and improving Adjusted EBITDA Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates. Key Financial Results: Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million; Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of $(31.2) millio

    2/25/26 4:01:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026

    Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-9843 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com. About Maravai M

    2/9/26 5:05:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $BHVN
    $CHRO
    $GENE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

    SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

    11/14/24 7:49:19 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/14/24 3:06:46 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Onconetix Inc.

    SC 13G - Onconetix, Inc. (0001782107) (Subject)

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $BHVN
    $CHRO
    $GENE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Chen Hung-Wen

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/19/26 2:02:48 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chen Hong-Jung

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/18/26 6:52:25 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chu Yi-An

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/18/26 6:46:11 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $BHVN
    $CHRO
    $GENE
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics, Inc. Company Operational Continuity Update

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics' strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to

    10/13/25 9:22:37 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care